621 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This Mendelian Randomization study provides robust genetic evidence for the causal long-term benefits and safety of GLP-1R agonists and SGLT2 inhibitors extending beyond their current use in high-risk patients. The fi…
This review is crucial for guiding future research and clinical practice in the rapidly evolving landscape of GLP-1 therapies, emphasizing a holistic approach to patient care. Understanding the psychological dimension…
This comprehensive real-world data provides crucial insights for clinicians and patients navigating treatment options for Type 2 Diabetes and obesity. The findings underscore Tirzepatide's potential for greater metabo…
The successful completion of this Phase III trial could establish IBI362 as a novel and effective treatment option for MAFLD, a condition with limited approved pharmacotherapies. Given the high prevalence of MAFLD in …
The successful demonstration of comparability between different CagriSema delivery devices is a critical step for its future availability and patient accessibility. This Phase 3 study aims to ensure that regardless of…
If CagriSema proves effective, it could represent a significant advancement in managing Chronic Kidney Disease in patients with Type 2 Diabetes and obesity, a population with high unmet medical needs. The potential fo…
This foundational Phase 1 study is critically important as it provides the initial human safety and tolerability data for semaglutide, a potent GLP-1 receptor agonist. Establishing a safe dose range in healthy individ…
As this PHASE 4 clinical trial is currently RECRUITING participants, specific findings are not yet available, with an estimated completion date of 2026-07-01. Researchers are meticulously collecting data from an estim…
This Phase III clinical trial is crucial because it could validate a new, potentially more accessible or cost-effective semaglutide formulation for obesity treatment. TQF3510 could offer an additional option for patie…
This completed Phase 1 study represents a critical milestone in the development of NNC0113-6856, providing foundational data on its safety and how it behaves in the human body. Establishing a favorable safety and phar…
This research provides compelling evidence that GLP-1 receptor agonists may exert direct cardioprotective effects against atrial fibrillation, extending beyond their well-documented benefits in weight management and g…
This study provides compelling evidence that oral semaglutide offers sustained, comprehensive cardiovascular protection beyond glycemic control and weight loss, significantly reducing the risk of major cardiovascular …
This detailed trial design and baseline data publication is crucial as it lays the groundwork for understanding the potential of Mazdutide as a significant new therapeutic option. If Mazdutide demonstrates superior or…
This comprehensive evaluation provides critical evidence supporting the superior efficacy of certain long-acting GLP-1 RAs in managing Type 2 Diabetes, particularly concerning glycemic control and weight reduction. Th…
This case report highlights a rare but significant potential adverse effect of semaglutide, suggesting that it might induce hypercapnia even in individuals with healthy lungs. This finding is critical as it expands th…
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct gluca…
The development of multi-agonist incretin therapies and novel non-incretin pathways represents a critical advancement, offering more potent and comprehensive treatment options for obesity and Type 2 Diabetes than ever…
This study identifies a novel mechanism by which Oroxylin A can combat NAFLD, highlighting its potential as a therapeutic agent. By modulating CPT1A through m6A methylation, Oroxylin A directly addresses the core meta…
This Phase 1 study is critically important as it seeks to understand the fundamental metabolic mechanisms of survodutide, a novel therapeutic candidate for obesity. If survodutide demonstrates superior or distinct ben…
This study provides compelling evidence that combining cagrilintide and semaglutide offers a highly effective and synergistic therapeutic strategy for achieving substantial and clinically meaningful weight loss, surpa…
The Cagrilintide-Semaglutide combination group demonstrated a remarkable mean body weight reduction of 22.6% from baseline over the 68-week study period, which was statistically significantly superior to all other gro…
This Phase 3 trial represents a critical step towards providing new, effective treatment options for children and adolescents struggling with overweight and obesity. If successful, the study could establish Cagrilinti…
Understanding the pharmacokinetic equivalence and performance of different CagriSema formulations and delivery devices is crucial for its continued development as a combination therapy for obesity. This study's findin…
This meta-analysis provides compelling evidence that CagriSema, combining a GLP-1 receptor agonist (semaglutide) with an amylin analog (cagrilintide), offers a substantially more potent and effective treatment option …
While specific pharmacokinetic data (e.g., Cmax, AUC values) are not detailed in this record, the study successfully completed its Phase 1 objectives, enrolling 40 participants and evaluating the drug exposures over a…
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
Cagrisema represents a highly potent and promising new therapeutic option for individuals struggling with obesity, offering superior weight loss efficacy and improved metabolic parameters compared to current gold-stan…
This comprehensive review underscores Semaglutide's position as a highly effective pharmacological intervention for obesity, offering substantial and sustained weight loss that can significantly improve health outcome…
This study is crucial because it focuses on affordable and accessible interventions for a population disproportionately affected by metabolic and cardiovascular diseases. Identifying effective, well-tolerated, and cos…
This Phase 1 study is a crucial step in the development of a potentially improved oral semaglutide formulation. Understanding the pharmacokinetics of oral semaglutide D under various dosing conditions is essential for…
This study is crucial for understanding the mechanisms by which semaglutide promotes weight loss and improves metabolic health, particularly at the 2.4 mg dose. The anticipated significant slowing of gastric emptying …
This large-scale data analysis is crucial for understanding the potential neuroprotective effects of different diabetes medications. If Semaglutide demonstrates a significantly lower risk of dementia/Alzheimer's disea…
This study provides compelling evidence, through a robust model-informed approach, that oral semaglutide 25 mg could offer a highly effective and convenient treatment option for obesity and type 2 diabetes. The conven…
These promising preclinical results for NeuroPep-X represent a significant step forward in the development of disease-modifying therapies for Alzheimer's Disease. The observed reductions in amyloid plaques and neuroin…
This case report highlights a rare but significant potential adverse effect of semaglutide, suggesting it may induce hypercapnia in susceptible individuals even with normal lung function. This finding underscores the …
This comprehensive critique offers crucial insights for clinicians and patients, suggesting that the current evidence does not strongly support a direct causal link between GLP-1 RAs and NAION, which may help alleviat…
Preserving lean body mass during weight loss is crucial for maintaining metabolic health, physical strength, and preventing conditions like sarcopenia (age-related muscle loss). If successful, this study could provide…